Roig J et al. |
13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents. |
|
Med Mal Infect |
pmid:17095177
|
Cavkaytar O et al. |
Testing for clarithromycin hypersensitivity: A diagnostic challenge in childhood. |
|
J Allergy Clin Immunol Pract |
pmid:26489714
|
Morimoto S et al. |
Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. |
1984 |
J. Antibiot. |
pmid:6706855
|
Pike VW et al. |
Semi-automated preparation of a 11C-labelled antibiotic--[N-methyl-11C]erythromycin A lactobionate. |
1984 |
Int J Appl Radiat Isot |
pmid:6231252
|
Fernandes PB et al. |
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. |
1986 |
Antimicrob. Agents Chemother. |
pmid:2949695
|
Segreti J et al. |
In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2952061
|
Benson CA et al. |
In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2952063
|
Barry AL et al. |
In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2952064
|
Chin NX et al. |
Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2953303
|
Bowie WR et al. |
In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2953304
|
Hanson CW et al. |
Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031). |
1987 |
J. Clin. Microbiol. |
pmid:2954995
|
Floyd-Reising S et al. |
In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2955742
|
Fernandes PB et al. |
Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2957954
|
Sasaki J et al. |
Microbial transformation of 6-O-methylerythromycin derivatives. |
1988 |
J. Antibiot. |
pmid:2971032
|
Adachi T et al. |
14-Hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human. |
1988 |
J. Antibiot. |
pmid:2971033
|
Waites KB et al. |
In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. |
1988 |
Antimicrob. Agents Chemother. |
pmid:2973283
|
Barry AL et al. |
Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test. |
1988 |
J. Clin. Microbiol. |
pmid:2976773
|
Chang HR and Pechère JC |
In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. |
1988 |
Antimicrob. Agents Chemother. |
pmid:2837140
|
Barry AL et al. |
In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. |
1988 |
Antimicrob. Agents Chemother. |
pmid:2840016
|
Adachi T et al. |
Crystal and molecular structure of (14R)-14-hydroxy-6-O-methylerythromycin A. |
1989 |
J. Antibiot. |
pmid:2737946
|
Gorzynski EA et al. |
Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. |
1989 |
Antimicrob. Agents Chemother. |
pmid:2524998
|
Fernandes PB et al. |
New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. |
1989 |
Antimicrob. Agents Chemother. |
pmid:2523688
|
Fernandes PB et al. |
In vitro and in vivo activities of clarithromycin against Mycobacterium avium. |
1989 |
Antimicrob. Agents Chemother. |
pmid:2530933
|
Kohno Y et al. |
Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. |
1989 |
Antimicrob. Agents Chemother. |
pmid:2526615
|
Tinel M et al. |
Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. |
1989 |
J. Pharmacol. Exp. Ther. |
pmid:2527301
|
Adachi T et al. |
Hydroxylation and N-demethylation of clarithromycin (6-O-methylerythromycin A) by Mucor circinelloides. |
1989 |
J. Antibiot. |
pmid:2529234
|
Naik S and Ruck R |
In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. |
1989 |
Antimicrob. Agents Chemother. |
pmid:2817858
|
Faghih R et al. |
Synthesis and antibacterial activity of (9S)-9-dihydroclarithromycin. |
1990 |
J. Antibiot. |
pmid:2147921
|
Perronne C et al. |
Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. |
1990 |
Antimicrob. Agents Chemother. |
pmid:2171421
|
Morimoto S et al. |
Chemical modification of erythromycins. III. In vitro and in vivo antibacterial activities of new semisynthetic 6-O-methylerythromycins A, TE-031 (clarithromycin) and TE-032. |
1990 |
J. Antibiot. |
pmid:2139023
|
Kohno Y et al. |
Autobacteriographic studies of clarithromycin and erythromycin in mice. |
1990 |
Antimicrob. Agents Chemother. |
pmid:2140497
|
Marchi E |
Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis. |
1990 |
Curr Med Res Opin |
pmid:2140546
|
Scaglione F |
Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. |
1990 |
Curr Med Res Opin |
pmid:2140547
|
Morimoto S et al. |
Chemical modification of erythromycins. VI. Structure and antibacterial activity of acid degradation products of 6-O-methylerythromycins A. |
1990 |
J. Antibiot. |
pmid:2141599
|
Hardy DJ et al. |
Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. |
1990 |
Antimicrob. Agents Chemother. |
pmid:2143642
|
Cacciapuoti AF et al. |
Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives. |
1990 |
J. Antibiot. |
pmid:2145254
|
Ferrero JL et al. |
Metabolism and disposition of clarithromycin in man. |
1990 Jul-Aug |
Drug Metab. Dispos. |
pmid:1976065
|
Straneo G and Scarpazza G |
Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. |
1990 Mar-Apr |
J. Int. Med. Res. |
pmid:2140330
|
Fraschini F |
Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis. |
1990 Mar-Apr |
J. Int. Med. Res. |
pmid:2140331
|
Rastogi N et al. |
Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1667250
|
Rastogi N and Labrousse V |
Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1828135
|
Ji B et al. |
Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1828136
|
Lu MY et al. |
A polymer carrier system for taste masking of macrolide antibiotics. |
1991 |
Pharm. Res. |
pmid:1829521
|
Perronne C et al. |
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1656860
|
Morgan DK et al. |
A reversed-phase high-performance liquid chromatographic method for the determination and identification of clarithromycin as the drug substance and in various dosage forms. |
1991 |
J Pharm Biomed Anal |
pmid:1831386
|
Dautzenberg B et al. |
Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. |
1991 |
Am. Rev. Respir. Dis. |
pmid:1832527
|
Rotsch TD et al. |
Determination of clarithromycin as a contaminant on surfaces by high-performance liquid chromatography using electrochemical detection. |
1991 |
Pharm. Res. |
pmid:1833731
|
Jorgensen JH et al. |
Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1834012
|
Truffot-Pernot C et al. |
Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1834015
|
Gelber RH et al. |
Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. |
1991 |
Antimicrob. Agents Chemother. |
pmid:1648889
|